|
1
|
Cunningham D, Atkin W, Lenz HJ, Lynch HT,
Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet.
375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ng SC and Wong SH: Colorectal cancer
screening in Asia. Br Med Bull. 105:29–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sung JJ, Lau JY, Young GP, Sano Y, Chiu
HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, et al: Asia
Pacific consensus recommendations for colorectal cancer screening.
Gut. 57:1166–1176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shao YC, Chang YY, Lin JK, Lin CC, Wang
HS, Yang SH, Jiang JK, Lan YT, Lin TC, Li AF, et al: Neoadjuvant
chemotherapy can improve outcome of colorectal cancer patients with
unresectable metastasis. Int J Colorectal Dis. 28:1359–1365. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohhara Y, Fukuda N, Takeuchi S, Honma R,
Shimizu Y, Kinoshita I and Dosaka-Akita H: Role of targeted therapy
in metastatic colorectal cancer. World J Gastrointest Oncol.
8:642–655. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Graham DM, Coyle VM, Kennedy RD and Wilson
RH: Molecular subtypes and personalized therapy in metastatic
colorectal cancer. Curr Colorectal Cancer Rep. 12:141–150. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA, and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McCubrey JA, Steelman LS, Abrams SL, Lee
JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA,
D'Assoro AB, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT
pathways in malignant transformation and drug resistance. Adv
Enzyme Regul. 46:249–279. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Modest DP, Ricard I, Heinemann V,
Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven
U, Arnold D, von Weikersthal LF, et al: Outcome according to KRAS-,
NRAS- and BRAF-mutation as well as KRAS mutation variants: Pooled
analysis of five randomized trials in metastatic colorectal cancer
by the AIO colorectal cancer study group. Ann Oncol. 27:1746–1753.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Andreatos N, Ronnekleiv-Kelly S, Margonis
GA, Sasaki K, Gani F, Amini N, Wilson A and Pawlik TM: From bench
to bedside: Clinical implications of KRAS status in patients with
colorectal liver metastasis. Surg Oncol. 25:332–338. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen J, Guo F, Shi X, Zhang L, Zhang A,
Jin H and He Y: BRAF V600E mutation and KRAS codon 13 mutations
predict poor survival in Chinese colorectal cancer patients. BMC
Cancer. 14:8022014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Chen Y, Wang D, Wang G, He L and Suo
J: Detection of KRAS mutations and their associations with
clinicopathological features and survival in Chinese colorectal
cancer patients. J Int Med Res. 40:1589–1598. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
De Roock W, Jonker DJ, Di Nicolantonio F,
Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M,
Piessevaux H, et al: Association of KRAS p.G13D mutation with
outcome in patients with chemotherapy-refractory metastatic
colorectal cancer treated with cetuximab. JAMA. 304:1812–1820.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guerrero S, Casanova I, Farré L, Mazo A,
Capellà G and Mangues R: K-ras codon 12 mutation induces higher
level of resistance to apoptosis and predisposition to
anchorage-independent growth than codon 13 mutation or
proto-oncogene overexpression. Cancer Res. 60:6750–6756.
2000.PubMed/NCBI
|
|
17
|
Samowitz WS, Curtin K, Schaffer D,
Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras
mutations in colon cancers to tumor location, stage, and survival:
A population-based study. Cancer Epidemiol Biomarkers Prev.
9:1193–1197. 2000.PubMed/NCBI
|
|
18
|
Margonis GA, Kim Y, Sasaki K, Samaha M,
Amini N and Pawlik TM: Codon 13 KRAS mutation predicts patterns of
recurrence in patients undergoing hepatectomy for colorectal liver
metastases. Cancer. 122:2698–2707. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang H, Zheng X, Ji T, Fu L, Bai D, Liao
Y, Zhang H, Ding Y and Zheng L: Comparative screening of K-ras
mutations in colorectal cancer and lung cancer patients using a
novel real-time PCR with ADx-K-ras Kit and Sanger DNA sequencing.
Cell Biochem Biophys. 62:415–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li ZZ, Wang F, Zhang ZC, Wang F, Zhao Q,
Zhang DS, Wang FH, Wang ZQ, Luo HY, He MM, et al: Mutation
profiling in chinese patients with metastatic colorectal cancer and
its correlation with clinicopathological features and anti-EGFR
treatment response. Oncotarget. 7:28356–28368. 2016.PubMed/NCBI
|
|
21
|
Favoriti P, Carbone G, Greco M, Pirozzi F,
Pirozzi RE and Corcione F: Worldwide burden of colorectal cancer: A
review. Updates Surg. 68:7–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Price TJ, Bruhn MA, Lee CK, Hardingham JE,
Townsend AR, Mann KP, Simes J, Weickhardt A, Wrin JW, Wilson K, et
al: Correlation of extended RAS and PIK3CA gene mutation status
with outcomes from the phase III AGITG MAX STUDY involving
capecitabine alone or in combination with bevacizumab plus or minus
mitomycin C in advanced colorectal cancer. Br J Cancer.
112:963–970. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tejpar S, Stintzing S, Ciardiello F,
Tabernero J, Van Cutsem E, Beier F, Esser R, Lenz HJ and Heinemann
V: Prognostic and predictive relevance of primary tumor location in
patients with RAS wild-type metastatic colorectal cancer:
Retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA
Oncol. Oct 10–2016.(Epub ahead of print).
|
|
25
|
Li FH, Shen L, Li ZH, Luo HY, Qiu MZ,
Zhang HZ, Li YH and Xu RH: Impact of KRAS mutation and PTEN
expression on cetuximab-treated colorectal cancer. World J
Gastroenterol. 16:5881–5888. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen
H, Tang J and Chen Q: KRAS, BRAF and PIK3CA mutations and the loss
of PTEN expression in Chinese patients with colorectal cancer. PLoS
One. 7:e366532012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frattini M, Saletti P, Romagnani E, Martin
V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F and
Mazzucchelli L: PTEN loss of expression predicts cetuximab efficacy
in metastatic colorectal cancer patients. Br J Cancer.
97:1139–1145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nadal E, Chen G, Prensner JR, Shiratsuchi
H, Sam C, Zhao L, Kalemkerian GP, Brenner D, Lin J, Reddy RM, et
al: KRAS-G12C mutation is associated with poor outcome in
surgically resected lung adenocarcinoma. J Thorac Oncol.
9:1513–1522. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tejpar S, Celik I, Schlichting M,
Sartorius U, Bokemeyer C and Van Cutsem E: Association of KRAS G13D
tumor mutations with outcome in patients with metastatic colorectal
cancer treated with first-line chemotherapy with or without
cetuximab. J Clin Oncol. 30:3570–3577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ward RL, Todd AV, Santiago F, O'Connor T
and Hawkins NJ: Activation of the K-ras oncogene in colorectal
neoplasms is associated with decreased apoptosis. Cancer.
79:1106–1113. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bournet B, Muscari F, Buscail C, Assenat
E, Barthet M, Hammel P, Selves J, Guimbaud R, Cordelier P and
Buscail L: KRAS G12D mutation subtype is a prognostic factor for
advanced pancreatic adenocarcinoma. Clin Transl Gastroenterol.
7:e1572016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ihle NT, Byers LA, Kim ES, Saintigny P,
Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, et al:
Effect of KRAS oncogene substitutions on protein behavior:
Implications for signaling and clinical outcome. J Natl Cancer
Inst. 104:228–239. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guibert N, Ilie M, Long E, Hofman V,
Bouhlel L, Brest P, Mograbi B, Marquette CH, Didier A, Mazieres J
and Hofman P: KRAS mutations in lung adenocarcinoma: Molecular and
epidemiological characteristics, methods for detection, and
therapeutic strategy perspectives. Curr Mol Med. 15:418–432. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li WQ, Kawakami K, Ruszkiewicz A, Bennett
G, Moore J and Iacopetta B: BRAF mutations are associated with
distinctive clinical, pathological and molecular features of
colorectal cancer independently of microsatellite instability
status. Mol Cancer. 5:22006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yokota T, Ura T, Shibata N, Takahari D,
Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K and
Yatabe Y: BRAF mutation is a powerful prognostic factor in advanced
and recurrent colorectal cancer. Br J Cancer. 104:856–862. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Imamura Y, Morikawa T, Liao X, Lochhead P,
Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis
KM, et al: Specific mutations in KRAS codons 12 and 13, and patient
prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer
Res. 18:4753–4763. 2012. View Article : Google Scholar : PubMed/NCBI
|
